07:35 AM EDT, 08/14/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) Thursday said its second-quarter net loss narrowed.

Net loss narrowed to $2.7 million, or $0.09 per share, from $5.7 million, or $0.18 per share, in the prior year period. The result beat the consensus analyst estimate of a loss of $0.10 per share, according to FactSet.

Second-quarter revenue declined 2% to $14.2 million. The decrease was due to lower royalty revenues and FX rate fluctuations.

HLS will introduce two cholesterol-lowering drugs, Nexletol and Nexlizet, in Canada, which it believes can more than double the size of its cardiovascular business. Health Canada approval is expected by year-end and the company plans to launch the medicines in the second quarter of next year, it said.

"Our year-to-date results reflect continued execution on our key strategic priorities as we position the company to resume its growth trajectory," said Craig Millian, chief executive officer. "We remain on track to achieve full-year guidance, with strong underlying performance demonstrated by 29% year-to-date Adjusted EBITDA growth, robust cash flow generation, and continued balance sheet strengthening through significant debt repayments."